Sarah Spencer
Investor Relations Contact presso VOR BIOPHARMA INC.
Profilo
Sarah Spencer is currently the Head-Investor & Media at Vor Biopharma, Inc. She previously worked as a Media Relations Contact at GSK Plc and as the Vice President-Corporate Communications at Astellas Gene Therapies, Inc. from 2019 to 2021.
Ms. Spencer obtained an undergraduate degree from the State University of New York at Buffalo.
Posizioni attive di Sarah Spencer
| Società | Posizione | Inizio |
|---|---|---|
| VOR BIOPHARMA INC. | Investor Relations Contact | - |
Precedenti posizioni note di Sarah Spencer
| Società | Posizione | Fine |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Public Communications Contact | 01/04/2021 |
| GSK PLC | Public Communications Contact | - |
Formazione di Sarah Spencer
| State University of New York at Buffalo | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GSK PLC | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Sarah Spencer
